ChiCTR2000034006
尚未开始
/
/
/
2020-06-21
/
/
diabetic retinopathy, diabetic macular oedema
A randomised controlled trial for investigation of the safety and efficacy of treating diabetic macular edema using Noctura 400 sleep mask
A randomised controlled study investigating the safety and efficacy of treating diabetic macular edema using Noctura 400 sleep mask
The aim of the evaluation is to compare and observe the efficacy of two different light emitted levels of Noctura 400 sleep mask on 300 patients with early DMO over a period of 12 months. 150 patients will be assigned randomly to each group. One group will receive the standard treatment of 2 scotopic trolands and the other will receive the lower level of light being tested which is 0.03 scotopic trolands. The results of the two groups will be compared. Results will be compared the efficacy of treatment in the two arms and their significance in the treatment of diabetic macular edema and to corelate with the level of compliance in each arm. Proposing that a low level of light will provide similar efficacy with better compliance In this study the analysis will focus on the change in key measures of diabetic macular oedema and the classification level of diabetic retinopathy. Observations will also include the need to administer standard treatments in parallel with mask use. An interim analysis will be carried out at 6 months, to ensure the study is powered correctly and to allow early publication of data if a strong efficacy signal is significant.
随机平行对照
其它
This will be a prospective, double-masked, randomized controlled study. Patients will be randomized into Noctura 400 sleep mask 0.03 scotopic trolands group or the standard 2 scotopic trolands group at a ratio of 1:1. The randomization sequence will be generated using a computerized randomization table kept central
The randomization sequence will be generated using a computerized randomization table kept centrally by a research assistant. All patients and investigators will be masked to the treatment allocation group. Assessors performing the follow-up assessments also will be masked to the patient allocation group.
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong; Health and Medical Research Fund 2019 (pending)
/
150
/
2020-11-01
2023-10-31
/
1. Adults (over 18 years old); 2. DM type 1 or 2; 3. Presence of diabetic macular oedema (DMO); 4. Patients who can give an HbA1c level throughout the study; 5. No previous treatments within 6months of baseline visit; 6. Any stage of non-proliferative diabetic retinopathy.；
登录查看1. Pregnant; 2. Advanced cataract or other media opacity which precludes a fundal view; 3. Any proliferative diabetic retinopathy including advanced diabetic eye disease (vitreous haemorrhage or tractional retinal detachment); 4. Unstable or poorly controlled diabetes (HbA1c levels >15); 5. Contraindications listed in the instruction of Noctura 400; 6. Unable to complete giving consent form.；
登录查看Research Fund Secretariat, Food and Health Bureau, The Government of HKSAR
/
药明康德2025-01-30
药明康德2025-01-30
药明康德2025-01-30
药明康德2025-01-30
药明康德2025-01-30
亚泰制药2025-01-30
小药说药2025-01-28
精准药物2025-01-28
亚泰制药2025-01-28
药明康德2025-01-27
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
